Comparison of the effect of empagliflozin and metformin on insulin resistance

Comparison of the effect of empagliflozin and metformin on insulin resistance in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250703066346N1

Enrollment

Registered

2025-09-13

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group1: Group A is treated with metformin 500 mg orally once a day for three months. Manufactured by Porsina Pharmaceutical Company. Intervention 2: Intervention group2: G

Eligibility

Sex/Gender

Female

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Women suffering from Polycystic ovary syndrome At the age of 15 to 55 years Suffering from Diabetes

Exclusion criteria

Exclusion criteria: Addiction

Design outcomes

Primary

Measure	Time frame
Changes in fasting blood sugar. Timepoint: These tests are checked before starting treatment and after three months of treatment. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParia Torabi

Islamic Azad University

Paria_torabi@yahoo.com+98 21 2660 2642

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026